Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors

Pancreas

Volumn 39, Issue 3, 2010, Pages 332-339

  Pham, Hung ^a   Chen, Monica ^a   Li, Aihua ^a   King, Jonathan ^a   Angst, Eliane ^a   Dawson, David W ^b   Park, Jenny ^a   Reber, Howard A ^a   Hines, O Joe ^a   Eibl, Guido ^a  

^a Hirshberg Laboratories for Pancreatic Cancer Research   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

15 hydroxyprostaglandin dehydrogenase; Cyclooxygenase 2; Microsomal prostaglandin E synthase; Prostaglandin E2; SNAI2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CARRIER PROTEIN; CYCLOOXYGENASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SNAIL HOMOLOG 1 PROTEIN; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CELL LINE; COLON CANCER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PANCREAS TUMOR; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BUTADIENES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 77950237476     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181baecbe     Document Type: Article

References (45)

1. Murakami M, Nakatani Y, Tanioka T, et al. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 2002;68-69:383-399.
2. Wang D, Dubois RN. Prostaglandin and cancer. Gut. 2006;55:115-122.
3. Lev-Ari S, Lichtenberg D, Arber N. Compositions for treatment of cancer and inflammation. Recent Patents Anticancer Drug Discov. 2008;3:55-62.
4. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003;2:1-7.
5. Eibl G, Bruemmer D, Okada Y, et al. PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306(4):887-897.
6. Clark JD, Lin LL, Kriz RW, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043-1051.
7. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182.
8. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003;7:207-222.
9. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
10. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000;275:32783-32792.
11. Jakobsson PJ, Thoren S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA. 1999;96:7220-7225.
12. Mancini JA, Blood K, Guay J, et al. Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem. 2001;267:4469-4475.
13. Tai HH, Ensor CM, Tong M, et al. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002;68-69:483-493.
14. Gee JR, Montoya RG, Khaled HM, et al. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol. 2003;21:266-270.
15. Quidville V, Segond N, Pidoux E, et al. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology. 2004;145:2561-2571.
16. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217-3223.
17. Cho H, Oliveira MA, Tai HH. Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. Arch Biochem Biophys. 2003;419:139-146.
18. Tong M, Ding Y, Tai HH. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis. 2006;27: 2170-2179.
19. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res. 2007; 67:5587-5593.
20. Matsuo M, Ensor CM, Tai HH. Characterization of the genomic structure and promoter of the mouse NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene. Biochem Biophys Res Commun. 1997;235:582-586.
21. Inukai T, Inoue A, Kurosawa H, et al. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell. 1999;4: 343-352.
22. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of lipids from animal tissue. J Biol Chem. 1957;226: 497-509.
23. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, et al. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug and MAPK. J Cell Biol. 2003;163: 847-857.
24. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer. Cancer Res. 2006;66:5338-5345.
25. Mann JR, Backlund MG, Buchanan FG, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and Snail increases prostaglandin E2 and promotes cancer progression. Cancer Res. 2006;66:6649-6656.
26. Hasan S, Satake M, Dawson DW, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas. 2008;37:121-127.
27. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
28. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
29. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362.
30. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
31. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
32. Dragovich T, Burris H 3rd, Loehrer P, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol. 2008; 31:157-162.
33. Appel MJ, van Garderen-Hoetmer A, Woutersen RA. Effects of dietary linoleic acid on pancreatic carcinogenesis in rats and hamsters. Cancer Res. 1994;54:2113-2120.
34. Matsubayashi H, Infante JR, Winter J, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6:1569-1575.
35. Hermanova M, Trna J, Nenutil R, et al. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol. 2008;20:732-739.
36. Bergmann F, Breinig M, Höpfner M, et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol. 2009;104:171-181.
37. Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem. 2002;131:781-784.
38. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003;74:143-153.
39. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.
40. Slice LW, Chiu T, Rozengurt E. Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways. J Biol Chem. 2005;280:1582-1593.
41. Pham H, Shafer LM, Slice LW. CREB-dependent cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression is mediated by protein kinase C and calcium. J Cell Biochem. 2006;98:1653-1666.
42. Pham H, Chong B, Vincenti R, et al. Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J Cell Physiol. 2008;214:96-109.
43. Gou Q, Liu CH, Ben-Av P, et al. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3¶-untranslated region. Biochem Biophys Res Commun. 1998;242:508-512.
44. Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3¶-untranslated region. J Biol Chem. 2000;275:11750-11757.
45. Lee HK, Jeong S. Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3¶-UTR. Nucleic Acids Res. 2006;34:5705-5714.